(PharmaNewsWire.Com, June 13, 2017 ) Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.
Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Albireo Pharma Inc Arena Pharmaceuticals Inc CymaBay Therapeutics Inc Eisai Co Ltd Enanta Pharmaceuticals Inc Genextra Spa Genfit SA GenKyoTex SA Gilead Sciences Inc GlaxoSmithKline Plc MediGene AG NGM Biopharmaceuticals Inc Novartis AG Retrophin Inc Shire Plc Virobay Inc.
Number of Products under Development for Primary Biliary Cirrhosis, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017 Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017 Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017 Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017 Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017 Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017 Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017 Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017 Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017 Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017 Primary Biliary Cirrhosis - Dormant Projects, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
